Early diagnosis of HPV-associated disease of the cervix uteri in women aged less than 30 years or older


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To assess the diagnostic importance of HPV testing performed by RT-RCR, liquid-based cytology with the PAP test in HPV-associated cervical diseases in patients aged less than 30years or older. Subjects and methods. Cytological, biopsy, and cytological materials were examined in 91 patients, including 35 women aged less than 30 years and 56patients over 30 years of age. The methods of RT-PCR, liquid-based cytology, histology, andp16 INK4A/Ki-67immunohistochemistry were used. Results. The efficiency of detecting CIN2+ in the HPV DNA test in patients aged less than 30 years and in those older than 30 years of age was the following: a sensitivity of 81.8 and 90.5% and a specificity of 30.4 and 47.2%, respectively; that of the PAP test was as follows: a sensitivity of 45.5 and 71.4% and a specificity of 100.0 and 97.2%, respectively. Conclusion. Early diagnosis of HPV-associated diseases of the cervix uteri should be based on a set of the cytological technique and HPV DNA testing irrespective of age.

Full Text

Restricted Access

About the authors

Evgeniya Altarovna Kogan

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: koganevg@gmail.com
MD, PhD Professor, Head of the Pathology Department

Nafisa Mynavarovna Faizullina

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: naflsa05@inbox.ru
PhD, senior research associate of the Pathology Department

Jiajing Li

I.M. Sechenov First Moscow State Medical University

Email: greenjing@qq.com
postgraduate student of anatomic pathology department

Tatiana Alexandrovna Demura

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: uursula90@gmail.com
MD, PhD, senior research associate of the Pathology Department

Nikolay Vladimirovich Zharkov

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: nickzharkov@mail.ru
PhD, researcher, of the Pathology Department

Andrey Vladimirovich Kozachenko

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: a_kozachenko@oparina4.ru
MD, PhD, leading research associate of the Gynecological Department

Victoria Fedorovna Chernova

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: cernovav@mail.ru
postgraduate student of Polyclinic Department

Gyuldana Raufovna Bairamova

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: g_bairamova@oparina4.ru
MD, PhD, Head of the Polyclinic Department on clinical work

Prilepskaya Vera Prilepskaya

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: VPrilepskaya@mail.ru
MD, PhD, Head of the Polyclinic Department

References

  1. Castle P.E., Fetterman B., Thomas Cox J., Shaber R., Poitras N., Lorey T., Kinney W. The age-specific relationships of abnormal cytology and human papillomavirus DNA results to the risk of cervical precancer and cancer. Obstet. Gynecol. 2010; 116(1): 76-84.
  2. Whitlock E.P, Vesco K.K., Eder M., Lin J.S., Senger C.A., Burda B.U. Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. Preventive services task force. Ann. Intern. Med. 2011; 155(10): 687-97. W214-5.
  3. Confortini M., Bergeron C., Desai M., Negri G., Dalla Palma P., Montanari G. et al. Accuracy of liquid based cytology: comparison of the results obtained within a randomized controlled trial (the New Technologies for Cervical Cancer Screening Study) and an external group of experts. Cancer Cytopathol. 2010; 118(4): 203-8.
  4. Kocken M., Uijterwaal M.H., de Vries A.L., Berkhof J., Ket J.C., Helmerhorst T.J., Meijer C.J. High-risk human papillomavirus testing versus cytology in predicting post-treatment disease in women treated for high-grade cervical disease: a systematic review and meta-analysis. Gynecol. Oncol. 2012; 125(2): 500-7.
  5. Solomon D., Davey D., Kurman R., Moriarty A., O’Connor D., Prey M. et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002; 287(16): 2114-9.
  6. Castle P.E., Sadorra M., Lau T., Aldrich C., Garcia F.A., Kornegay J. Evaluation of a prototype real-time PCR assay for carcinogenic human papillomavirus (HPV) detection and simultaneous HPV genotype 16 (HPV16) and HPV18 genotyping. J. Clin. Microbiol. 2009; 47(10): 3344-7.
  7. Petry K.U., Schmidt D., Scherbring S., Luyten A., Reinecke-Luthge A., Bergeron C. et al. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology. Gynecol. Oncol. 2011; 121(3): 505-9.
  8. Fawcett T. An introduction to ROC analysis. Pattern Recognition Letters. 2006; 27: 861-74.
  9. Kim M.-J., Kim J.J., Kim S. Type-specific prevalence of high-risk human papillomavirus by cervical cytology and age: Data from the health check-ups of 7,014 Korean women. Obstet. Gynecol. Sci. 2013; 56(2): 110-20.
  10. Mesher D., Cuschieri K., Hibbitts S., Jamison J., Sargent A., Pollock K.G. et al. Type-specific HPV prevalence in invasive cervical cancer in the UK prior to national HPV immunisation programme: baseline for monitoring the effects of immunisation. J. Clin. Pathol. 2015; 68(2): 135-40.
  11. Tungsrithong N., Kasinpila C., Maneenin C. Lack of significant effects of Chlamydia trachomatis infection on cervical cancer risk in a nested case-control study in North-East Thailand. Asian Pac. J. Cancer Prev. 2014; 15(3): 1497-500.
  12. Rijkaart D.C., Berkhof J., Rozendaal L., van Kemenade F.J., Bulkmans N.W., Heideman D.A. et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 2012; 13(1): 78-88.
  13. Kurian E.M., Caporelli M.L., Baker S., Woda B., Cosar E.F., Hutchinson L. Cervista HR and HPV 16/18 assays vs hybrid capture 2 assay: outcome comparison in women with negative cervical cytology. Am. J. Clin. Pathol. 2011; 136(5): 808-16.
  14. Arbyn M., Roelens J., Cuschieri K., Cuzick J., Szarewski A., Ratnam S. et al. The APTIMA HPV assay versus the Hybrid Capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy. Int. J. Cancer. 2013; 132(1): 101-8.
  15. Ratnam S., Coutlee F., Fontaine D., Bentley J., Escott N., Ghatage P. et al. APTIMA HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer. J. Clin. Microbiol. 2011; 49(2): 557-64.
  16. Коган Е.А., Файзуллина Н.М., Цзяцзин Л., Демура Т.А., Козаченко А.В. Эффективность диагностики цервикальной интраэпителиальной неоплазии шейки матки с использованием комплекса методов: жидкостной цитологии, двойного иммуноокрашивания p16/Ki67 и ВПЧ тестирования. Акушерство и гинекология. 2014; 7: 43-7. [Kogan E.A., Faizullina N.M., Li Ts., Demura T.A., Kozachenko A.V. Efficiency of cervical intraepithelial neoplasia diagnosis using a set of methods: liquid-based cytology, p16/Ki-67 dual immunostaining and HPV testing. Akusherstvo i ginekologiya/Obstetrics and Gynecology. 2014; 7: 43-7. (in Russian)]
  17. Arbyn M., Roelens J., Buntinx F. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions. Cochrane Database Syst. Rev. 2013; (3): CD008054.
  18. Bergeron C., Giorgi-Rossi P., Cas F., Schiboni M.L., Ghiringhello B., Dalla Palma P. et al. Informed cytology for triaging HPV-positive women: substudy nested in the NTCC randomized controlled trial. J. Natl. Cancer Inst. 2015; 107(2). pii: dju423.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies